Real-life study of the epidemiological profile and adherence to the treatment of patients with severe allergic asthma using Omalizumab for 12 months
DOI:
https://doi.org/10.5433/1679-0367.2020v41n2Suplp321Keywords:
Severe allergic asthma, Omalizumab, Adherence.Abstract
Introduction: asthma is a hetereogeneous disease, characterized by chronic inflammation of the lower airways associated with different phenotypes. Omalizumab is used in addition to treatment when adequate asthma control is not achieved. This study shows the epidemiological profile and the adherence to the treatment of patients followed at the Medical Clinic of the State University Hospital of Londrina (AEHU-UEL) using omalizumab in the last 12 months. Methods: severe allergic asthma patients using omalizumab in the last 12 months were evaluated by means of secondary medical records. Results: forty patients were included and had complete medical record. The average age was 51.4 years mostly women (70%), white (48%), non-smoker (90%), overweight or obese (75%) and childhood asthma diagnosis (45%). The average treatment time was 8.1 years (SD0.8). There were co-morbidities in 85% of the patients, mainly rhinitis in 62.5% and GERD in 40%. There were exacerbations in 29 patients, leading to 8 hospitalizations (27.5%), 93% of exacerbators was missed at least one time. Strong association with rhinitis (p=0.07), and no disease control (p=0.22). Conclusion: the sample is comparable to other real-life studies in almost all epidemiological findings (age, sex, phenotype, time of diagnosis, disease control and smoking). The high number of absences and frequency of GERD and other comorbidities, and poor adhesion, may justify the high number of exacerbations and more difficulty to control the disease.Downloads
Download data is not yet available.
References
Abraham I, Alhossan A, Lee CS, Kutbi H, MacDonald K. “Real-life” effectiveness studies of omalizumab in adult patients with severe allergic asthma: Systematic review. Allergy Eur J Allergy Clin Immunol. 2016;71(5):593-610.
Barbosa MP, Almeida AB, Pereira C, Chen CW, Georgiou P, Peachey G. Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma. Rev. Port. Pneumol. 2015;21(6):151-6.
Cerci A Neto. Mudança no perfil do manejo da asma em uma cidade brasileira de médio porte após programa estruturado: dado após quatro anos de implantação. [tese]. Londrina: Universidade Estadual de Londrina; 2009.
Chen W, Marra CA, Lynd LD, Fitzgerald JM, Zafari Z, Sadatsafavi M. The natural history of severe asthma and influences of early risk factors: A population-based cohort study. Thorax. 2016;71(3):267-75.
Denlinger LC, Phillips BR, Ramrtnam S, Ross K, Bhakta NR, Cardet JC, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med. 2017;195(3):302-13.
Dias JG, Silva P, Mendes A, Costa C, Pedro E, Barbosa MP. Omalizumabe no tratamento da asma brônquica alérgica: Experiência num serviço de imunoalergologia. Rev. Port. Imunoalergologia. 2012;20(4):263-71.
Franco R, Campos H, Sarinho EC, Cerci A Neto. O custo da asma grave para o sistema público de saúde e para as famílias. Gaz Médica da Bahia. 2008;78(2):45-51.
Global Initiative for Asthma. Global strategy for asthma management and prevention. USA: GINA; 2016. p. 147.
Janson SL, Solari PG, Trzaskoma B, Chen H, Haselkorn T, ZazzaliJL. Omalizumab adherence in na observational study of patients with moderate to severe allergic asthma. Ann Allergy Asthma Immunol. [Internet]. 2015 June [cited 2018 Feb 4]; 114(6):516-21. Available in: http://www.ncbi.nlm.nih;gov/pubmed/26021894.
Osterberg L, Blaschke T. Adherence to medication. New Eng Journ Med. 2005;353:487-97.
Rubin AS, Souza-Machado A, Andrade-Lima M, Ferreira F, Honda A, Matozo TM. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma. 2012;49(3):288-93.
Serra-Batlles J, Plaza V, Morejn E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J. 1998;12(6):1322-6.
Sposato B, Scalese M, Latorre M, Scichilone N, Matucci A, Milanese M, et al. Effects of omalizumab in severe asthmatics across ages: A real-life Italian experience. Respir Med. 2016;119:141-9.
Stelmach R, Cerci A Neto, Fonseca ACDCF, Ponte EV, Alves G, Araujo-Costa IN, et al. A workshop on asthma management programs and centers in Brazil: reviewing and explaining concepts. J. Bras. Pneumol. 2015;41(1).
Wisnivesky JP, Lorenzo J, Lyn-Cook R, Newman T, Aponte A, Kiefer E, et al. Barriers to adherence to asthma management guidelines among inner-city primary care providers. Ann Allergy Asthma Immunol. 2008;101(3):264-70. doi: 10.1016/S1081-1206(10)60491-7.
Barbosa MP, Almeida AB, Pereira C, Chen CW, Georgiou P, Peachey G. Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma. Rev. Port. Pneumol. 2015;21(6):151-6.
Cerci A Neto. Mudança no perfil do manejo da asma em uma cidade brasileira de médio porte após programa estruturado: dado após quatro anos de implantação. [tese]. Londrina: Universidade Estadual de Londrina; 2009.
Chen W, Marra CA, Lynd LD, Fitzgerald JM, Zafari Z, Sadatsafavi M. The natural history of severe asthma and influences of early risk factors: A population-based cohort study. Thorax. 2016;71(3):267-75.
Denlinger LC, Phillips BR, Ramrtnam S, Ross K, Bhakta NR, Cardet JC, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med. 2017;195(3):302-13.
Dias JG, Silva P, Mendes A, Costa C, Pedro E, Barbosa MP. Omalizumabe no tratamento da asma brônquica alérgica: Experiência num serviço de imunoalergologia. Rev. Port. Imunoalergologia. 2012;20(4):263-71.
Franco R, Campos H, Sarinho EC, Cerci A Neto. O custo da asma grave para o sistema público de saúde e para as famílias. Gaz Médica da Bahia. 2008;78(2):45-51.
Global Initiative for Asthma. Global strategy for asthma management and prevention. USA: GINA; 2016. p. 147.
Janson SL, Solari PG, Trzaskoma B, Chen H, Haselkorn T, ZazzaliJL. Omalizumab adherence in na observational study of patients with moderate to severe allergic asthma. Ann Allergy Asthma Immunol. [Internet]. 2015 June [cited 2018 Feb 4]; 114(6):516-21. Available in: http://www.ncbi.nlm.nih;gov/pubmed/26021894.
Osterberg L, Blaschke T. Adherence to medication. New Eng Journ Med. 2005;353:487-97.
Rubin AS, Souza-Machado A, Andrade-Lima M, Ferreira F, Honda A, Matozo TM. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma. 2012;49(3):288-93.
Serra-Batlles J, Plaza V, Morejn E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J. 1998;12(6):1322-6.
Sposato B, Scalese M, Latorre M, Scichilone N, Matucci A, Milanese M, et al. Effects of omalizumab in severe asthmatics across ages: A real-life Italian experience. Respir Med. 2016;119:141-9.
Stelmach R, Cerci A Neto, Fonseca ACDCF, Ponte EV, Alves G, Araujo-Costa IN, et al. A workshop on asthma management programs and centers in Brazil: reviewing and explaining concepts. J. Bras. Pneumol. 2015;41(1).
Wisnivesky JP, Lorenzo J, Lyn-Cook R, Newman T, Aponte A, Kiefer E, et al. Barriers to adherence to asthma management guidelines among inner-city primary care providers. Ann Allergy Asthma Immunol. 2008;101(3):264-70. doi: 10.1016/S1081-1206(10)60491-7.
Downloads
Published
2020-11-21
How to Cite
1.
Soares FC, Nogueira RRS, Sugahara L, Passarelli P, Kauffmann R, Cerci Neto A. Real-life study of the epidemiological profile and adherence to the treatment of patients with severe allergic asthma using Omalizumab for 12 months. Semin. Cienc. Biol. Saude [Internet]. 2020 Nov. 21 [cited 2024 Nov. 24];41(2Supl):321-30. Available from: https://ojs.uel.br/revistas/uel/index.php/seminabio/article/view/38263
Issue
Section
Artigos
License
Copyright (c) 2020 Semina: Ciências Biológicas e da Saúde
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
adopts the CC-BY-NC license for its publications, the copyright being held by the author, in cases of republication we recommend that authors indicate first publication in this journal.
This license allows you to copy and redistribute the material in any medium or format, remix, transform and develop the material, as long as it is not for commercial purposes. And due credit must be given to the creator.
The opinions expressed by the authors of the articles are their sole responsibility.
The magazine reserves the right to make normative, orthographic and grammatical changes to the originals in order to maintain the cultured standard of the language and the credibility of the vehicle. However, it will respect the writing style of the authors. Changes, corrections or suggestions of a conceptual nature will be sent to the authors when necessary.
This Journal is licensed with a license Creative Commons Assignment-NonCommercial 4.0 International.
